Affitech Renews Exclusive Worldwide Phage Display License From DKFZ; 'Breitling' Patents Hold Key Position in Human Antibody Discovery Field.CHICAGO -- The human antibody company, Affitech AS, announced today at BIO 2006 that they have renewed an exclusive worldwide licensing agreement with DKFZ DKFZ Deutsches Krebsforschungszentrum (German Cancer Research Center, Heidelberg, Germany) (German Cancer Research Center The German Cancer Research Center (known as the Deutsches Krebs Forschungs Zentrum or simply DKFZ in German), is a cancer research center based in Heidelberg, Germany. It is a member of the Helmholtz Association, the largest scientific organization in Germany. ) of Heidelberg, Germany for the antibody library display patents, otherwise known as "Breitling" IP family. These patents cover the use of full-length pIII phage phage: see bacteriophage. phage - A program that modifies other programs or databases in unauthorised ways; especially one that propagates a virus or Trojan horse. See also worm, mockingbird. The analogy, of course, is with phage viruses in biology. protein as a scaffold scaffold Temporary platform used to elevate and support workers and materials during work on a structure or machine. It consists of one or more wooden planks and is supported by either a timber or a tubular steel or aluminum frame; bamboo is used in parts of Asia. in a phagemid vector, and are one of the fundamental patents for the phagemid display of antibody, antibody fragments and proteins. As the antibody therapeutic market continues to grow with a record number of candidates moving through pre-clinical and clinical trials, Affitech anticipates that all serious entrants in the antibody field will consider the use of these patents. This is backed by the fact that over the past couple of years, Affitech has successfully negotiated cross-licensing agreements involving Breitling IP with leading antibody companies such as Dyax and Xoma. The renewed terms provide Affitech the worldwide exclusive license until the expiry of the patents in the respective territories, and include the capability of Affitech to sublicense sub·li·cense n. A license giving rights of production or marketing of products or services to a person or company that is not the primary holder of such rights. tr.v. the IP to any company or organization worldwide. No other terms of the agreement were disclosed. Regarding the renewal of the Breitling IP licensing, Dr. Martin Welschof, Chief Executive Officer of Affitech commented: "We are delighted to have renewed this exclusive license and the accompanying sublicensing rights with DKFZ with whom we have had a long-standing relationship going back to the original development of phagemid-based antibody display system. The Breitling family occupies a key position in the antibody field. The IP applies not only to screening libraries, but extends to antibodies discovered and developed for use as diagnostics or therapeutics. With the announcement of this renewal, we expect further sublicensing agreements to follow those already signed with Dyax and Xoma." The DKFZ agreement represents another milestone as Affitech continues to progress towards becoming a product-focused human antibody therapeutics company. Several of its in-house discovered antibodies generated by its pioneering CBAS CBAS Command Budget Automated System CBAS Computrols Building Automation System (building automation software) CBAS Computerized Building Automation System CBAS Corporate Business Applications Support (TM) (Cell Based Antibody Selection) technology are currently undergoing pre-clinical development Pre-clinical development is a stage in the development of a new drug that begins before clinical trials (testing in humans) can begin, and during which important safety and pharmacology data is collected. . |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion